JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib
Disease Markers · 2024
DOI: 10.1155/2024/2906566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Markers, 2024. Verfasst von Indra Wijaya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjad…. Hauptthemen laut MEDLINE: Imatinib Mesylate, Janus Kinase 2, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitas Padjadjaran.
Abstract (Originalsprache)
Background
Chronic myeloid leukemia (CML) or chronic granulocytic leukemia is a myeloproliferative neoplasm indicated by the presence of the Philadelphia (Ph+) chromosome. First-line tyrosine kinase inhibitor, imatinib, is the gold standard for treatment. However, there has been known unresponsiveness to treatment, especially due to the involvement of other genes, such as the Janus kinase 2 (JAK2) gene. This study aimed to evaluate the relationships between JAK2 levels and complete hematological response (CHR), as well as early molecular response (EMR) after 3 months of imatinib treatment in patients with chronic phase CML.
Methods
Patients with Ph+ CML in the chronic phase (n = 40; mean age, 40 ± 11 years) were recruited to complete assessments consisting of clinical examination and blood test, including evaluation of complete blood counts and the JAK2 levels, at baseline and following 3 months of therapy with imatinib (at an oral dose of 400 mg per day). Subjects were divided into two groups according to the presence of CHR and EMR.
Results
JAK2 gene levels, phosphorylated, and total JAK2 proteins at baseline were significantly lower in the group with the presence of CHR and EMR. In addition, baseline JAK2 levels, including JAK2 gene expression, phosphorylated, and total JAK2 proteins, were negatively correlated with the presence of CHR and EMR.
Conclusions
Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.
- Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
- Department of Child Health, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.
- Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.
ORCID-Profile: Indra Wijaya, Anita Rahmawati
Förderung
- Universitas Padjadjaran
Zitieren
APA
Wijaya, I., Bashari, M. H., Reniarti, L., Rahmawati, A., & Roesli, R. M. A. (2024). JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib. Disease Markers. https://doi.org/10.1155/2024/2906566
Vancouver
Wijaya I, Bashari MH, Reniarti L, Rahmawati A, Roesli RMA. JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib. Disease Markers. 2024. doi:10.1155/2024/2906566
BibTeX
@article{Wijaya2024,
author = {Wijaya, Indra and Bashari, Muhammad H and Reniarti, Lelani and Rahmawati, Anita and Roesli, Rully M A},
title = {JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib},
journal = {Disease Markers},
year = {2024},
doi = {10.1155/2024/2906566}
}
EUVIMED